Michael McGinley - President - Biologicals & Pharmaceuticals of Heska Corporation

Person placeholder

Michael McGinley

President - Biologicals & Pharmaceuticals since 2013

Total compensation: $786,366
Age: 56

Dr. Michael J. McGinley, Ph.D., is no longer President - Biologicals & Pharmaceuticals of Heska Corporation effective March 31, 2018. He previously served as President and Chief Operating Officer from January 2009 to February 2013, Vice President, Global Operations from April through December 2008, Vice President, Operations and Technical Affairs and General Manager, Heska Des Moines from January 2002 to April 2008 and in other positions beginning in June 1997. Prior to joining the Company, Dr. McGinley held positions with Bayer Animal Health and Fort Dodge Laboratories. He holds Ph.D. and MS degrees in Immunobiology from Iowa State University and successfully completed the Advanced Management Program at the Harvard Business School in 2008.

Heska Corporation logo

Heska Corporation develops, manufactures, and markets advanced veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. It operates through two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and IV pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus Chewable Tablets for the preventive treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels. The Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and independent third-party distributors, as well as trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

  • Heska Corporation, 3760 Rocky Mountain Avenue, Loveland 80538, United States
  • heska.com
  • 970-493-7272